Shen Yun, Yang Junjun, Zhao Jing, Xiao Changji, Xu Caimin, Xiang Yang
Technical Service Centre of Family Planning and Reproductive Health, National Research Institute for Family Planning, Beijing 100081, People׳s Republic of China.
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, People׳s Republic of China.
Exp Cell Res. 2015 Jun 10;334(2):207-18. doi: 10.1016/j.yexcr.2015.04.010. Epub 2015 Apr 24.
Human choriocarcinoma, a highly curable solid tumour, is exceptionally sensitive to methotrexate-based chemotherapy at the metastatic stage. The present study aimed to investigate the molecular basis for this resistance to methotrexate therapy occurs in some cases, and these patients subsequently die from progressive and advanced disease.
The autophagy and apoptotic activity regulated by PERK/ATF4 axis in methotrexate-resistant JEG-3 and parental cells were evaluated with western blotting and chromatin immunoprecipitation (ChIP). The regulatory relationships among the reactive oxygen species (ROS), JNK/p62 axis, PERK/ATF4-mediated apoptosis and autophagy were assessed with western blotting, RT-PCR, fluorescence-activated cell sorting as well as ChIP.
The decreased apoptosis in methotrexate-resistant JEG-3 cells was observed with an up-regulation of protective autophagy, suggesting a switch from apoptosis to autophagy, which was regulated via the PERK/ATF4 pathway under condition of endoplasmic reticulum (ER) stress. Further experiments demonstrated that this cell death switch was regulated by ROS-mediated JNK/p62 pathway and subsequently lead to the resistance of choriocarcinoma cells to methotrexate treatment.
This study provides evidence to explain a survival mechanism of the switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals in methotrexate-resistant choriocarcinoma cells and may implicate the chemotherapy of methotrexate resistance in choriocarcinoma.
人绒毛膜癌是一种高度可治愈的实体瘤,在转移阶段对基于甲氨蝶呤的化疗异常敏感。本研究旨在探究在某些情况下对甲氨蝶呤治疗产生耐药性的分子基础,这些患者随后死于疾病进展和晚期。
采用蛋白质免疫印迹法和染色质免疫沉淀法(ChIP)评估甲氨蝶呤耐药的JEG-3细胞和亲本细胞中由PERK/ATF4轴调节的自噬和凋亡活性。通过蛋白质免疫印迹法、逆转录-聚合酶链反应(RT-PCR)、荧光激活细胞分选以及ChIP评估活性氧(ROS)、JNK/p62轴、PERK/ATF4介导的凋亡和自噬之间的调控关系。
观察到甲氨蝶呤耐药的JEG-3细胞中凋亡减少,同时保护性自噬上调,提示从凋亡向自噬的转变,这在内质网(ER)应激条件下通过PERK/ATF4途径调节。进一步实验表明,这种细胞死亡转变受ROS介导的JNK/p62途径调控,随后导致绒毛膜癌细胞对甲氨蝶呤治疗产生耐药性。
本研究提供了证据,解释了甲氨蝶呤耐药的绒毛膜癌细胞中通过ROS介导的JNK/p62信号从ER应激诱导的凋亡向自噬转变的生存机制,可能对绒毛膜癌中甲氨蝶呤耐药的化疗有启示意义。